Order results by:
| Issue | Title | |
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... comparing clinical effectiveness and safety of apixaban with warfarin (ARISTOTLE) and acetylsalicylic acid ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| "... showed that only therapy with rivaroxaban (out of three NOAC) in comparison to warfarin reduced the risk ..." | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..." | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| "... and systemic thromboembolism. For patients that were treated by warfarin international normalization ratio (INR ..." | ||
| Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
| "... of ASA, are also presented in the article. The benefits of apixaban over warfarin for reducing the risk ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| "... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..." | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| "... of three NOAC) in comparison to warfarin reduced the risk of stroke/systemic embolism and ischemic stroke ..." | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| "... of the main studies didn't yield or exceeded warfarin concerning balance of efficiency and safety. However ..." | ||
| Vol 16, No 3 (2020) | Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue | Abstract similar documents |
| O. D. Ostroumova, I. V. Goloborodova | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... and systemic thromboembolic (STE) complications as warfarin, although DOACs were associated with less risk ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... in the frequency of myocardial infarction between any of the doses of dabigatran and warfarin, and the risk ..." | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... cardioversion. Vitamin K antagonists (warfarin) more often used to prepare for electrical cardioversion. However ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| "... of them oral anticoagulants were used mainly from the group of vitamin K antagonists, most often warfarin ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... .g. warfarin), have a predictable manifestation of the anticoagulant effect and the possibility of using ..." | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... ,3%) patients received vitamin K antagonist (warfarin). The international normalized ratio in the target range ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... " of the OAC is warfarin, which has proved effectiveness in all categories of patients with AF. A whole group ..." | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
| Vol 7, No 2 (2011) | PECULIAR PROPERTIES OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION. IS IT POSSIBLE TO DO THE TREATMENT SAFE? | Abstract similar documents |
| I. V. Zotova, D. A. Zateyshchikov | ||
| Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
| E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
| "... with persistent nonvalvular atrial fibrillation receiving warfarin and direct oral anticoagulants (DOAC ..." | ||
| Vol 14, No 3 (2018) | THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE | Abstract similar documents |
| I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..." | ||
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... Apixaban is oral anticoagulant, it is widely used in prevention of stroke in non-valvular atrial ..." | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| "... % compared with warfarin in the patients aged 75 years and older. The safety of rivaroxaban has been ..." | ||
| Vol 15, No 4 (2019) | Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen | Abstract similar documents |
| A. I. Kochetkov, O. D. Ostroumova | ||
| "... of evidence showing their high safety and efficacy, which in some cases exceed those of warfarin, and also ..." | ||
| Vol 2, No 3 (2006) | ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? | Abstract similar documents |
| I. A. Latfullin, A. A. Podolskaya | ||
| "... of action and clinical efficiency of antithrombotic and antiplatelet medicines such as acetylsalicylic acid ..." | ||
| Vol 8, No 4 (2012) | WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE | Abstract similar documents |
| E. N. Dankovtseva, S. L. Arkhipov, D. A. Zateyshchikov | ||
| "... Analysis of the current literature data on the use of warfarin in patients with cardioembolic ..." | ||
| Vol 11, No 5 (2015) | Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism | Abstract similar documents |
| A. V. Rudakova | ||
| "... these for other NOACs, and the additional cost of apixaban therapy compared with LMWH/warfarin proved to be highly ..." | ||
| Vol 12, No 5 (2016) | The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin | Abstract similar documents |
| I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich | ||
| "... Aim. To study the effect of rivaroxaban compared with warfarin on the incidence of cardioembolic ..." | ||
| Vol 10, No 3 (2014) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... of management of patients with atrial fibrillation. Many years of practice and experience of warfarin use ..." | ||
| Vol 11, No 6 (2015) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... of management of patients with atrial fibrillation. Many years of practice and experience of warfarin use ..." | ||
| Vol 20, No 5 (2024) | Effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis of clinical trials | Abstract similar documents |
| E. M. Mezhonov, Z. M. Safiullina, Y. A. Vyalkina, S. V. Shalaev | ||
| "... " or "dabigatran" or "apixaban" or "rivaroxaban" and "vitamin K antagonist" or "warfarin" and "outcomes". ROBINS-I ..." | ||
| Vol 12, No 3 (2016) | THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE | Abstract PDF (Eng) similar documents |
| A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko | ||
| "... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..." | ||
| Vol 7, No 5 (2011) | ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| Yu. B. Belousov, I. S. Yavelov, D. Yu. Belousov, E. V. Afanasieva | ||
| "... Aim. To analyze the structure of expenses associated with warfarin dose adjustment ..." | ||
| Vol 11, No 5 (2015) | Practical aspects of apixaban use in clinical practice: continuing the theme | Abstract similar documents |
| S. N. Bel'diev | ||
| "... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..." | ||
| Vol 10, No 3 (2014) | EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION | Abstract similar documents |
| "... European Medicines Agency approved apixaban use in cardioversion. ..." | ||
| Vol 11, No 2 (2015) | PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST | Abstract similar documents |
| D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii | ||
| "... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..." | ||
| Vol 11, No 6 (2015) | Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events | Abstract similar documents |
| O. V. Shatalova | ||
| "... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..." | ||
| Vol 7, No 1 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... fibrillation. Factors of warfarin therapy efficacy, as well as the possibility of new antithrombotic drugs ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... and apixaban in patients with non-valvular atrial fibrillation (AF) and to assess the impact of the both ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... of warfarin, a questionnaire of food preferences was used. The questionnaire allows you to assess the risk ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... , rivaroxaban, apixaban, and edoxaban) over the vitamin K antagonist warfarin in elderly patients with geriatric ..." | ||
| Vol 15, No 5 (2019) | Clinical Case: Atypical Warfarin-induced Skin Necrosis | Abstract similar documents |
| T. V. Kondratieva, L. V. Popova, S. S. Karachev, A. S. Lishuta, M. Z. Kanevskaya | ||
| "... Warfarin-induced skin necrosis (WISN) is a rare complication of antivitamin K therapy, which occurs ..." | ||
| Vol 16, No 1 (2020) | Decrease in Efficacy of Warfarin as a Result of Drug-Drug Interaction (Case Report) | Abstract similar documents |
| N. T. Vatutin, G. G. Taradin, G. A. Ignatenko, E. S. Gasendich, A. V. Harchenko, I. B. Povaljaeva | ||
| "... considering a frequent administration of several drugs having different drug-drug interactions. Warfarin ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..." | ||
| Vol 5, No 3 (2009) | SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS | Abstract similar documents |
| E. S. Kropacheva | ||
| "... The safety of anticoagulant therapy is discussed. Warfarin position in prevention of thrombotic ..." | ||
| Vol 6, No 5 (2010) | THE INVASIVE DENTAL PROCEDURES IN PATIENTS TREATING WITH WARFARIN: POSSIBILITIES AND PROSPECTS FOR SAFETY | Abstract similar documents |
| T. V. Kozlova, I. M. Makeyeva, V. Y. Doroshina, S. I. Bokareva | ||
| "... in the perioperative continuation or termination of warfarin therapy is shown. Potential of the local hemostatic agents ..." | ||
| Vol 6, No 4 (2010) | ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS | Abstract similar documents |
| A. Y. Rychkov, N. Y. Khor'kova, A. A. Bliznyakov | ||
| "... Appropriate use of warfarin is not in routine clinical practice despite convincing data ..." | ||
| Vol 8, No 2 (2012) | QUALITY OF LIFE AND ITS DYNAMICS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER LEAVING THE INTERNATIONAL CLINICAL TRIAL | Abstract similar documents |
| E. L. Artanova, L. E. Kon'shina, I. M. Sokolov, Y. G. Shvarts | ||
| "... with warfarin after leaving the international clinical trial. Material and Methods. Patients with AF who were ..." | ||
| Vol 15, No 4 (2019) | Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... results demonstrate a favorable efficiency and safety profile of rivaroxaban in comparison with warfarin ..." | ||
| Vol 8, No 4 (2012) | THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... . Along with traditional drugs (acetylsalicylic acid, warfarin) rivaroxaban is specially considered ..." | ||
| Vol 14, No 5 (2018) | Excessive Hypocoagulation in Therapy with Warfarin within Polypharmacy: Using online database Multi-Drug Interaction Checker and Graphic “Time-Effect-Drug Administration” to Eliminate Adverse Drug Event (Case Report) | Abstract similar documents |
| G. S. Krasnov, I. V. Kazancev | ||
| "... . As a result of analysis, it was described two drug interactions led to minor bleeding: warfarin ..." | ||
| Vol 14, No 5 (2018) | Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban ..." | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| "... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..." | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 7, No 4 (2011) | SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS | Abstract similar documents |
| E. L. Artanova, E. V. Saleeva, I. M. Sokolov, Y. G. Shvarts | ||
| "... Aim. To study the relations of clinical characteristics and individual warfarin dose titration ..." | ||
| Vol 9, No 4 (2013) | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky | ||
| "... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..." | ||
| Vol 16, No 2 (2020) | Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev | ||
| "... anticoagulants (DOACs) (χ2=1.44; p<0.49, Pearson) and significantly more in individuals taking warfarin ..." | ||
| Vol 16, No 3 (2020) | Thrombosis of Prosthetic Cardiac Valve: Difficulties of Diagnostics on the Example of a Clinical Case with Lethal Outcome | Abstract similar documents |
| A. A. Novoselova, S. S. Yakushin | ||
| "... with the installation of mechanical prosthesis into the aortal position and further warfarin medication, with absence ..." | ||
| Vol 17, No 2 (2021) | Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic | Abstract similar documents |
| S. M. Mamatov, B. Kanat kyzy, A. O. Musakeev, N. K. Kinderbaeva, T. J. Tagaev | ||
| "... warfarin, while only 11.8% had adequate INR control after one year of follow-up. Rivaroxaban was prescribed ..." | ||
| Vol 17, No 2 (2021) | Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage | Abstract similar documents |
| A. S. Gerasimenko, V. S. Gorbatenko, O. V. Shatalova, V. I. Petrov | ||
| Vol 15, No 4 (2019) | Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko | ||
| "... complications in atrial fibrillation, including those with concomitant renal pathology, was considered warfarin ..." | ||
| Vol 17, No 6 (2021) | Changes in Prescribing Antithrombotic Therapy in Patients with Atrial Fibrillation in the Multidisciplinary Hospital in Volgograd from 2012 to 2020 | Abstract similar documents |
| A. S. Gerasimenko, O. V. Shatalova, V. S. Gorbatenko, V. I. Petrov | ||
| "... .001), decreased the frequency of administration of warfarin from 71,9% to 18,3% (р<0.001). The frequency of use ..." | ||
| Vol 8, No 1 (2012) | PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov | ||
| "... the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings from ..." | ||
| Vol 14, No 1 (2018) | THE CONTROL OF INTERNATIONAL NORMALISED RATIO IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH WARFARIN IN OUTPATIENT AND HOSPITAL SETTINGS: DATA FROM RECVASA REGISTRIES | Abstract similar documents |
| M. M. Loukianov, S. Yu. Martsevich, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, T. A. Gomova, M. N. Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, M. A. Bichurina, L. A. Matskevich, E. N. Belova, V. G. Klyashtorny, E. V. Kudryashov, A. D. Deev, O. M. Drapkina, s. A. Boytsov | ||
| "... in patients with atrial fibrillation (AF) receiving anticoagulant therapy with warfarin. Material and methods ..." | ||
| Vol 21, No 2 (2025) | Anticoagulant therapy in patients with cardioembolic subtype of ischemic stroke and atrial fibrillation | Abstract similar documents |
| E. A. Naryshkina, M. I. Chashkina, E. S. Zadykyan, N. K. Kurbanalieva, E. M. Zakaryan, M. V. Serova, D. A. Andreev, A. G. Komarova, K. E. Eroshkin, A. A. Kulesh, D. A. Sychev | ||
| "... on outpatient ACT were included; rivaroxaban (n=56), apixaban (n=30), dabigatran etexilate (n=11), and warfarin ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..." | ||
| Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... ) and rs4148738 (c.2692-2236C>T) genes on the plasma concentration of apixaban, on changes in prothrombin ..." | ||
| Vol 7, No 4 (2011) | LEFT VENTRICULAR CLOT LYSIS DUE TO COMBINED ANTICOAGULANT THERAPY WITH WARFARIN AND FRAXIPARINE IN PATIENT WITH DILATED CARDIOMYOPATHY AND CHRONIC HEART FAILURE. THE CLINICAL CASE | Abstract similar documents |
| O. V. Uskova, K. O. Sobolev, G. E. Gendlin, A. V. Melekhov | ||
| "... anticoagulant therapy with warfarin and fraxiparine in patient with dilated cardiomyopathy, congestive heart ..." | ||
| Vol 12, No 5 (2016) | Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms | Abstract PDF (Eng) similar documents |
| Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev | ||
| "... compared with patients of warfarin group. Mutations in CYP2C9 gene were detected in 32.9%, VKORC1 – in 68 ..." | ||
| Vol 14, No 1 (2018) | NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| Ju. P. Skirdenko, N. A. Nikolayev | ||
| "... of food products that can affect anticoagulant therapy with warfarin does not have special regional ..." | ||
| Vol 9, No 5 (2013) | APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA | Abstract similar documents |
| D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev | ||
| "... response to oral anticoagulants is considered. Possible tactics of warfarin dosing and new oral ..." | ||
| Vol 15, No 1 (2019) | Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City | Abstract similar documents |
| A. A. Tuchkov, N. G. Gogolashvili, R. A. Yaskevich | ||
| "... % at the prehospital stage, of which 19.8% of patients took warfarin and 12.2% – direct OAC. The target level ..." | ||
| Vol 15, No 4 (2019) | According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | Abstract similar documents |
| Company Pfizer | ||
| Vol 15, No 4 (2019) | The Therapy with Oral Anticoagulants in Patients with Atrial Fibrillation in Outpatient and Hospital Settings (Data from RECVASA Registries) | Abstract similar documents |
| M. M. Loukianov, S. Yu. Martsevich, O. M. Drapkina, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, E. M. Pozdnyakova, T. A. Gomova, E. E. Fedotova, M. N Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, E. Y. Andreenko, V. G. Klyashtorny, E. V. Kudryashov, E. Yu. Okshina, M. A. Panagopulu, S. A. Boytsov | ||
| "... (1335 from 3169 patients; age 69.1±10.4 years, 43% men), including warfarin (817 patients; 26%) and non ..." | ||
| Vol 20, No 6 (2024) | Multivessel coronary artery stenting complicated by stent thrombosis in the setting of hereditary thrombophilia: a clinical case | Abstract similar documents |
| Z. M. Safiullina, E. M. Mezhonov, S. V. Viatchinina, Yu. A. Vyalkina, A. Kh. Sereshcheva | ||
| "... clinical trials on the efficacy of direct oral anticoagulants remain insufficient. Therefore, warfarin ..." | ||
| Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
| I. S. Yavelov | ||
| Vol 10, No 2 (2014) | ANALYSIS OF ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT ATRIAL FIBRILLATION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, A. S. Maslakov | ||
| "... . Acetylsalicylic acid was prescribed to 0.7% of cases (n=2), warfarin – to 5% (n=12). High risk of thromboembolic ..." | ||
| Vol 7, No 6 (2011) | CORONARY EMBOLISM WITH FRAGMENTED THROMBUS FROM THE LEFT VENTRICLE IN PATIENT WITH POSTINFARCTION ANEURYSM | Abstract similar documents |
| Yu. F. Salakhova, S. V. Gar'kina, T. V. Kislukhin, D. V. Duplyakov, V. S. Ivanov, E. R. Perunova, E. I. Bazhenova, S. E. Burnazyan, S. M. Khokhlunov | ||
| "... therapy (acetylsalicylic acid, clopidogrel, warfarin) was made on the 4th day of disease onset taking ..." | ||
| Vol 13, No 1 (2017) | ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY | Abstract similar documents |
| E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko | ||
| "... that risk associated with acetylsalicylic acid (ASA) use in patients ≥75 years can overweigh its potential ..." | ||
| Vol 10, No 6 (2014) | PHARMACOEPIDEMIOLOGIC ANALYSIS OF HOSPITAL TREATMENT OF PATIENTS WITH CEREBRAL INFARCTION AND ATRIAL FIBRILLATION | Abstract similar documents |
| N. V. Mikheeva, O. V. Reshetko, N. V. Furman | ||
| "... .12.2011. Results. Acetylsalicylic acid was prescribed to 66.7% of patients, warfarin – 3.9%. At that target level ..." | ||
| Vol 8, No 3 (2012) | RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... -salicylic acid, warfarin). Efficacy and safety of rivaroxaban is considered on the basis of the results ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..." | ||
| Vol 7, No 4 (2011) | ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID | Abstract similar documents |
| I. N. Bokarev, L. V. Popova | ||
| "... An experience of acetylsalicylic acid (ASA) clinical use since its synthesis in 1887 ..." | ||
| 1 - 100 of 203 Items | 1 2 3 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
